Reading cancer's earliest fingerprints in a single tube of blood - before a mammogram ever sees it.
THE MARK. The ARNA Genomics wordmark - a seven-person biotech turning cell-free DNA into an early-warning system for cancer.
The Dispatch
The hardest problem in cancer is not always treatment. It is timing. By the time a tumor announces itself, the odds have often already shifted. ARNA Genomics US Inc., a small biotechnology company based in San Francisco, is built around the moment before that - the quiet window when disease leaves traces in the bloodstream but has not yet declared itself.
Founded in 2013, ARNA develops what it calls multiomics liquid-biopsy technology. In plain terms: a blood draw, run through proprietary chemistry, that looks for the molecular signals cancer sheds into plasma. The company's lead product, ARNA Breast, is an in vitro diagnostic aimed at catching early-stage breast cancer by combining oncogene fragment analysis in cell-free DNA with measurements of plasma enzyme activity.
The idea is not to replace mammography or biopsy outright, but to add a noninvasive layer - a test that could flag risk from routine blood work, without a needle in tissue. A second program, ARNA-1, aims further: a general cancer marker designed to detect oncological disease without first knowing where the tumor sits.
The science has academic footing. A proof-of-concept study run with the Research Center for Personalized Oncology at Sechenov University reported 100% sensitivity and 85% specificity on plasma samples from women with newly diagnosed breast cancer and healthy volunteers. The company cites overall accuracy above 90%, with the caveat that larger, blinded trials are the real test.
ARNA is led by founder and CEO Egor Melnikov, an entrepreneur whose earlier ventures spanned advertising, logistics and IT before he turned to diagnostics. The scientific spine comes from elsewhere: chief scientific officer Anatoliy Melnikov brings four decades in molecular biology, and the scientific board is chaired by Charles R. Cantor, a member of the National Academy of Sciences.
In September 2020, the company closed a $3.5 million Series A led by the venture fund Xploration Capital - modest by biotech standards, but pointed. Before it, ARNA had spent roughly $1.5 million across seven years. The new capital was earmarked for clinical validation and multicenter trials across the US, Europe and other regions. In a field where the chemistry is often the easy part and the validation is the mountain, that is where ARNA now stands.
By The Numbers
The Problem
Survival odds in cancer are tied tightly to stage at detection. Standard screening - mammography, ultrasound, MRI, tissue biopsy - is powerful but can be invasive, uncomfortable, or reach patients later than anyone would like. ARNA's thesis is that the earliest signal is already circulating in the blood, if you can read it accurately and affordably.
The Difference
A single biomarker can mislead. ARNA layers several signals at once - DNA fragmentation, methylation patterns and plasma enzyme activity - using its own amplification and hybridization methods. Reading multiple molecular dimensions together is the point: it is designed to make an early call more robust than any one measurement alone.
"Raised funding will allow us to conduct strong evidential studies, which will let us make our tests available to patients in the nearest future."
Products & Services
An in vitro diagnostic for early-stage breast cancer that combines oncogene fragment analysis in cell-free DNA with plasma enzyme activity measurement - from a routine blood sample.
A general cancer marker designed to detect oncological disease from blood without first localizing the tumor - a location-agnostic early signal.
The core technology: novel DNA amplification, hybridization and methylation analysis methods that read multiple molecular cancer signals from plasma at once.
The Evidence
Early study on 80 women; confidence intervals are wide. A registered multicenter trial (NCT04890340) compares ARNA Breast against mammography, ultrasound, MRI and biopsy.
Business Model
ARNA is a diagnostics developer commercializing proprietary test systems. The plan is to distribute validated assays to clinics, laboratories, hospitals and patients following regulatory clearance, with a staged rollout envisioned across the US, Europe, the CIS, India and China - a mix of B2B and B2C channels.
The Market
Liquid biopsy is a crowded, fast-moving field. ARNA sits alongside larger players such as GRAIL, Guardant Health, Freenome, Exact Sciences and Delfi Diagnostics. Its wager is a focused, affordable multiomics approach to early breast cancer - depth in one indication rather than breadth across many.
Expertise
Founder & CEO. Serial entrepreneur across advertising, logistics and IT before biotech; recipient of a 2021 CEO Global Award.
Co-founder & Chief Scientific Officer, and inventor behind the platform - 40+ years in molecular biology.
Scientific Board Chairman and member of the National Academy of Sciences - academic weight behind the venture.
Also on the team: George Nikitin (CTO, co-founder), Vladimir Savanovich (CIIO, co-founder), Tatiana Vener (COO), Takeshi Sano (Scientific Director).
Milestones
The company is established to develop liquid-biopsy technology for early cancer detection.
A general cancer marker is created to detect disease without tumor localization.
A study with Sechenov University reports high sensitivity and specificity for ARNA Breast.
Xploration Capital leads a Series A to fund clinical validation of ARNA Breast.
The company registers a multicenter study and CEO Egor Melnikov wins a CEO Global Award.
Worth Knowing
Questions
It develops multiomics liquid-biopsy tests that detect cancer from a blood sample, with a focus on early-stage breast cancer.
An in vitro diagnostic assay that analyzes cell-free DNA fragments and plasma enzyme activity to detect early breast cancer noninvasively.
A proof-of-concept study reported 100% sensitivity and 85% specificity; the company cites over 90% accuracy, pending larger validation trials.
It closed a $3.5M Series A led by Xploration Capital in September 2020, after roughly $1.5M in earlier financing.
It was founded in 2013 by Egor Melnikov (CEO), Anatoliy Melnikov, George Nikitin, Vladimir Savanovich and Sergey Dolgachev.
Connect